Blog

  • How low protein intake affects your body: 8 warning symptoms to look out for

    How low protein intake affects your body: 8 warning symptoms to look out for

    Protein is a vital nutrient that supports almost every function in the human body. From maintaining muscles and skin to assisting in hormone and enzyme production, its importance cannot be overstated. A deficiency in protein, even a mild one, can have widespread effects on physical health, as per Healthline. Although severe deficiency is rare in developed countries, a low intake over time may still contribute to several health complications.

    Swelling and Puffiness: A Sign of Edema

    One of the most visible signs of severe protein deficiency is edema, which presents as swelling or puffiness, particularly in the skin. This occurs due to reduced levels of albumin, a blood protein responsible for maintaining fluid balance. When albumin is low, fluid escapes into tissues, causing noticeable swelling. Though this is more common in extreme cases such as kwashiorkor, it highlights how crucial protein is for fluid regulation.

    Fat Accumulation in the Liver

    Fatty liver is another issue linked to inadequate protein intake. In such cases, fat begins to build up in liver cells, potentially progressing to inflammation, scarring, or even liver failure. The exact mechanism isn’t fully understood, but it may involve disrupted fat transport processes and changes in the gut microbiome or cellular function.

    Impact on Skin, Hair, and Nails

    Protein also contributes to the health of skin, hair, and nails. Deficiency can result in brittle nails, thinning hair, or even conditions like telogen effluvium, where more hair enters the shedding phase. In severe cases, such as in children with kwashiorkor, the skin may show discoloration or peeling.

    Loss of Muscle Mass and Strength

    The body breaks down muscle tissue to compensate for low protein intake, leading to muscle wasting over time. This is particularly concerning in older adults, where even a moderate shortfall can accelerate muscle loss, known as sarcopenia. Experts recommend older individuals consume higher amounts of protein than the standard daily allowance to preserve muscle health.

    Weakened Bones and Higher Fracture Risk

    Bone strength is also influenced by protein. Studies show that individuals with higher protein intake tend to have better bone mineral density, particularly in the spine and hips. Over time, insufficient protein can contribute to weakened bones and a greater risk of fractures.

    Stunted Growth in Children

    Children are particularly vulnerable to protein deficiency. Inadequate intake can severely affect growth and development. Stunting, a condition where growth is restricted, affects millions of children worldwide and is often directly linked to malnutrition and lack of protein in the diet.

    Increased Susceptibility to Infections

    The immune system relies on protein to function properly. A lack of it can impair the production of antibodies, which are crucial for fighting infections. Some studies have found that individuals with higher protein intake experience fewer infections, particularly respiratory illnesses.

    Increased Appetite and Calorie Intake

    Low protein levels may also lead to increased hunger. The body’s effort to restore protein balance can result in heightened appetite, often leading to higher intake of calorie-dense foods rich in carbohydrates and fats. This imbalance can eventually contribute to weight gain and metabolic issues.

    The recommended daily protein intake for adults is around 46 grams for women and between 52 to 56 grams for men. These numbers are considered minimums to prevent deficiency. However, those who are physically active or elderly may benefit from significantly higher intake—ranging from 0.6 to 0.9 grams per pound of body weight. In some cases, resistance training individuals may require up to 1.3 grams per pound.

    While protein deficiency is rare in balanced diets, signs like fatigue, swelling, brittle nails, and muscle loss may indicate a problem. Identifying and addressing protein gaps in your diet can prevent long-term health issues. Including a variety of protein-rich foods such as eggs, dairy, legumes, lean meats, and soy can help maintain optimal health.

    Continue Reading

  • Pohankova bests Pareja to keep Wimbledon girls’ crown in Slovak hands

    Pohankova bests Pareja to keep Wimbledon girls’ crown in Slovak hands

    WIMBLEDON — The unseeded Mia Pohankova became the second consecutive Slovak girls’ singles champion at Wimbledon with a 6-3, 6-1 defeat of No. 6 seed Julieta Pareja in a 68-minute final between two 16-year-olds.

    In 2024, Renata Jamrichova became Slovakia’s first ever junior champion at SW19 after defeating Emerson Jones in the final, and Pohankova followed in her footsteps after coming from 3-1 down in the first set to win 11 of the last 12 games. The Levice native conceded only five points behind her first serve, and fired 13 winners to Pareja’s three.

    Pohankova also impressed with the variety in her game. As well as her easy power on the forehand side, particularly useful when turning points from defense to attack, she also deployed the slice to excellent effect and won nine of 13 points at net. This included the best shot of the match, at 3-3 in the first set — having approached off a knifing backhand slice down the line, Pohankova leapt to pull off a high, angled backhand volley winner.

    Afterwards, the teenager admitted she had been nervous initially, but had settled as the match had gone on.

    “When I step on the court and you saw the crowd and, like, stadium is so big, little bit nervous first three games,” Pohankova said. “I just trying to play, and I’m trying to do my best, like I did … When I lead 3-0 second set, I feel like this my game.”

    As 2018 junior champion Iga Swiatek was sealing her first senior crown over on Centre Court, Pohankova also underlined her intention to follow in the Pole’s footsteps.

    “I need to won like real Wimbledon, not juniors,” she said. “I think this is just start.”

    Pohankova’s Wimbledon run opened with a 7-6(4), 6-1 of home hope and US Open junior champion Mika Stojsavljevic, and also included a 6-2, 6-2 rout of junior No. 1 Jones in the quarterfinals. She dropped just one set all week — to Brazilian 15-year-old Nauhany Vitoria Leme Da Silva in a 6-3, 5-7, 6-3 third-round win.

    Pareja had not played on grass before this year, but put together an 11-match winning streak to start off on the surface. The American won the J300 warm-up tournament in Roehampton last week, and defeated both Hannah Klugman and Mingge Xu, the two other leading British junior hopes, en route to the Wimbledon final.

    Both Pohankova and Pareja have also begun to make an impact at pro level. Pareja reached the final round of US Open qualifying as a wild card last year, then became the first 2009-born player to compete and win matches in a WTA main draw after making the Bogota semifinals in April. She’s currently ranked No. 340.

    Pohankova has played a limited pro schedule to date — just seven tournaments since her debut in October 2023, five of which were in Slovakia — but has already delivered impressive results. She won the 2024 Bratislava ITF W75 last October, notching her first Top 100 win on the way over Oceane Dodin, and raised her year-end ranking from No. 978 to No. 544 last season. Pohankova made her WTA qualifying debut in Berlin three weeks ago, falling to Katerina Siniakova 7-6(5), 6-1 in the first round, and is now ranked No. 465.

    Continue Reading

  • This new wireless charger fills your e-bike battery while it’s parked

    This new wireless charger fills your e-bike battery while it’s parked

    Forget fumbling with cables or hunting for batteries – TILER is making electric bike charging as seamless as parking your ride. The Dutch startup recently introduced its much-anticipated TILER Compact system, a plug-and-play wireless charger engineered to transform the user experience for e-bike riders.

    At the heart of the new system is a clever combo: a charging kickstand that mounts directly to almost any e‑bike, and a thin charging mat that you simply park over. Once you drop the kickstand and it lands on the mat, the bike begins charging automatically via inductive transfer – no cable required. According to TILER, a 500 Wh battery will fully charge in about 3.5 hours, delivering comparable performance to traditional wired chargers.

    It’s an elegantly simple concept (albeit a bit chunky) with a convenient upside: less clutter, fewer broken cables, and no more need to bend over while feeling around for a dark little hole.

    TILER claims its system works with about 75% of existing e‑bike platforms, including those from Bosch, Yamaha, Bafang, and other big bames. The kit uses a modest 150 W wireless power output, which means charging speeds remain practical while keeping the system lightweight (the tile weighs just 2 kg, and it’s also stationary).

    Advertisement – scroll for more content

    TILER has already deployed over 200 charging points across Western Europe, primarily serving bike-share, delivery, hospitality, and hotel fleets. A recent case study in Munich showed how a cargo-bike operator saved approximately €1,250 per month in labor costs, avoided thousands in spare batteries, and cut battery damage by 20%. The takeaway? Less maintenance, more uptime.

    Now shifting to prosumer markets, TILER says the Compact system will hit pre-orders soon, with a €250 price tag (roughly US $290) for the kickstand plus tile bundle. To get in line, a €29 refundable deposit is currently required, though they say it is refundable at any point until you receive your charger. Don’t get too excited just yet though, there’s a bit of a wait. Deliveries are expected in summer 2026, and for now are covering mostly European markets.

    The concept isn’t entirely new. We’ve seen the idea pop up before, including in a patent from BMW for charging electric motorcycles. And the efficacy is there. Skeptics may wonder if wireless charging is slower or less efficient, but TILER says no. Its system retains over 85% efficiency, nearly matching wired charging speeds, and even pauses at 80% to protect battery health, then resumes as needed. The tile is even IP67-rated, safe for outdoor use, and about as bulky as a thick magazine.

    Electrek’s Take

    I love the concept. It makes perfect sense for shared e-bikes, especially since they’re often returning to a dock anyway. As long as people can be trained to park with the kickstand on the tile, it seems like a no-brainer.

    And to be honest, I even like the idea for consumers. I know it sounds like a first-world problem, but bending over to plug something in at floor height is pretty annoying, not to mention a great way to throw out your back if you’re not exactly a spring chicken anymore. Having your e-bike start charging simply by parking it in the right place is a really cool feature! I don’t know if it’s $300 cool, but it’s pretty cool!

    FTC: We use income earning auto affiliate links. More.

    Continue Reading

  • Scooter Braun Reacts to Justin Bieber’s Album ‘Swag’

    Scooter Braun Reacts to Justin Bieber’s Album ‘Swag’

    Justin Bieber‘s former manager Scooter Braun has publicly shared his thoughts on the singer’s new album Swag just one day after its release.

    Braun, whose split from Bieber drew headlines when first revealed (Braun retired from music management in June 2024), decided to offer his thoughts on Swag to the mix, by writing on his Instagram Story on Saturday, “Been having a beautiful start to the weekend and been getting a lot of texts about how I feel about Justin’s new album.. so I will just leave this here.. This is without a doubt, the most authentically Justin Bieber album to date. It’s beautiful, raw, and truly him. And that matters.”

    He continued, “I’ve had the privilege of witnessing his growth for almost two decades. Along every journey, there comes a time when an artist fully steps into their own — and that’s what he’s done here. He’s poured his soul into this project, and you can feel it in every single run.”

    Braun also noted that “Daisies” is his favorite track on the record, and that Bieber’s tone is the “best in the world.”

    On Friday, Bieber dropped the 21-track Swag, his seventh studio album and first in four years since 2021’s Justice. The project, a blend of genres and subject matters, delves into everything from the singer’s relationship with his wife, Hailey Bieber, and the paparazzi to mental health issues and colloquially “Standing on Business,” as one song is titled, over pop, R&B, soul, hip-hop and gospel melodies. The rollout also not shying away from the artist’s latest meme-able act, with one billboard on Sunset Blvd reading “It’s Not Clocking to You” in reference to the words Bieber recited during his viral standoff with photogs outside Malibu’s Soho Beach House last month.

    Generally well-received, Swag has been praised by listeners as “mature” and “authentic,” with one fan account calling the album his “declaration of independence.” Bieber’s label, Def Jam, announced on Saturday that the album had reached the top spot on both the global and U.S. Apple Music and Spotify album charts.

    Braun discovered the now 31-year-old Canadian singer via YouTube in 2008 when Bieber was just 13 years old, and soon launched him into pop superstardom. After 15 years of working together, the pair’s relationship began to sour following the financial fallout from Bieber’s failed Justice world tour in 2022. Earlier this month, it was announced that Braun, who built his management business working with additional acts such as Ariana Grande, J Balvin and Demi Lovato, is transitioning out of his role as CEO of HYBE America to an advisory position in which he will join the Board of the Directors of the South Korean entertainment conglomerate HYBE, serving as a director and a senior adviser to chairman Bang Si-Hyuk.


    Continue Reading

  • Scooter Braun Calls ‘Swag’ the “Most Authentically Justin Bieber Album to Date”

    Scooter Braun Calls ‘Swag’ the “Most Authentically Justin Bieber Album to Date”

    Justin Bieber’s former manager Scooter Braun has publicly shared his thoughts on the singer’s new album Swag just one day after its release.

    Braun, whose split from Bieber drew headlines when first revealed (Braun retired from music management in June 2024), decided to offer his thoughts on Swag to the mix, by writing on his Instagram Story on Saturday, “Been having a beautiful start to the weekend and been getting a lot of texts about how I feel about Justin’s new album.. so I will just leave this here.. This is without a doubt, the most authentically Justin Bieber album to date. It’s beautiful, raw, and truly him. And that matters.”

    More from The Hollywood Reporter

    He continued, “I’ve had the privilege of witnessing his growth for almost two decades. Along every journey, there comes a time when an artist fully steps into their own — and that’s what he’s done here. He’s poured his soul into this project, and you can feel it in every single run.”

    Braun also noted that “Daisies” is his favorite track on the record, and that Bieber’s tone is the “best in the world.”

    On Friday, Bieber dropped the 21-track Swag, his seventh studio album and first in four years since 2021’s Justice. The project, a blend of genres and subject matters, delves into everything from the singer’s relationship with his wife, Hailey Bieber, and the paparazzi to mental health issues and colloquially “Standing on Business,” as one song is titled, over pop, R&B, soul, hip-hop and gospel melodies. The rollout also not shying away from the artist’s latest meme-able act, with one billboard on Sunset Blvd reading “It’s Not Clocking to You” in reference to the words Bieber recited during his viral standoff with photogs outside Malibu’s Soho Beach House last month.

    Generally well-received, Swag has been praised by listeners as “mature” and “authentic,” with one fan account calling the album his “declaration of independence.” Bieber’s label, Def Jam, announced on Saturday that the album had reached the top spot on both the global and U.S. Apple Music and Spotify album charts.

    Braun discovered the now 31-year-old Canadian singer via YouTube in 2008 when Bieber was just 13 years old, and soon launched him into pop superstardom. After 15 years of working together, the pair’s relationship began to sour following the financial fallout from Bieber’s failed Justice world tour in 2022. Earlier this month, it was announced that Braun, who built his management business working with additional acts such as Ariana Grande, J Balvin and Demi Lovato, is transitioning out of his role as CEO of HYBE America to an advisory position in which he will join the Board of the Directors of the South Korean entertainment conglomerate HYBE, serving as a director and a senior adviser to chairman Bang Si-Hyuk.

    Best of The Hollywood Reporter

    Sign up for THR’s Newsletter. For the latest news, follow us on Facebook, Twitter, and Instagram.


    Continue Reading

  • Study reveals hidden heart risks in women with Type 2 Diabetes

    Study reveals hidden heart risks in women with Type 2 Diabetes

    England [UK], July 12 (ANI): Women with type 2 diabetes are nearly twice as likely as men to have undetected heart damage, according to a new study by Leicester researchers.

    Advertisement

    The research is one of the most detailed investigations into coronary microvascular dysfunction (CMD) to uncover sex-specific risk patterns in people with no signs of heart disease.

    CMD is a form of early, silent heart damage caused by impaired blood flow in the heart’s smallest vessels. Using advanced MRI scans and data taken from four studies conducted at the NIHR Leicester Biomedical Research Centre (BRC), researchers found that 46% of the women with type 2 diabetes had signs of CMD, compared to just 26% of the men.

    “We’re seeing early warning signs of heart disease that aren’t picked up through routine checks, and it’s women who seem to be most affected,” said NIHR Research Professor at the University of Leicester, Gerry McCann, lead investigator of the study.

    “What makes this study remarkable is that all participants were asymptomatic, which means they had no diagnosed heart problems, no chest pain, and no shortness of breath. Yet the scans told a different story.”

    Dr Gaurav Gulsin, co-author and NIHR Clinical Lecturer, added: “The study also found that the drivers of CMD differ by sex. In women, CMD was most strongly linked to higher body weight (BMI). However, in men, higher blood pressure was the more significant factor.

    “This suggests we may need to rethink how we assess cardiovascular risk and that women and men could warrant sex-specific treatments.”

    This paper also marks a milestone for the NIHR Leicester BRC, showcasing the power of cross-theme collaboration of the Cardiovascular, Lifestyle, and Diabetes research teams to uncover complex insights that would not be possible in isolation.

    “This is a fantastic example of what happens when teams across specialisms come together with a shared goal to spot disease earlier and improve outcomes for patients. It’s exactly what the BRC was set up to do,” said Professor of Diabetes Medicine, Melanie Davies CBE, Director of the NIHR Leicester BRC and a co-author of the publication.

    “The findings have significant implications for future prevention strategies. Interventions like weight loss for women and blood pressure control for men could help reduce early heart damage long before it progresses into heart failure, which is a condition especially common in people with type 2 diabetes.” (ANI)

    (This content is sourced from a syndicated feed and is published as received. The Tribune assumes no responsibility or liability for its accuracy, completeness, or content.)


    Continue Reading

  • FDA Grants Orphan Drug Designation to Quemliclustat in Pancreatic Cancer

    FDA Grants Orphan Drug Designation to Quemliclustat in Pancreatic Cancer

    Quemliclustat plus gemcitabine and nab-paclitaxel chemotherapy outperformed median OS benchmarks in patients with metastatic PDAC.

    The investigational small molecule CD73 inhibitor quemliclustat was granted orphan drug designation for the treatment of patients with pancreatic cancer by the FDA, according to a press release from the developer, Arcus Biosciences.1

    “The orphan drug designation indicates the importance of developing new treatment options for rare diseases like pancreatic cancer, which has the highest mortality rate of all major cancers, and which has seen few treatment advancements over the past 30 years,” stated Richard Markus, MD, PhD, chief medical officer at Arcus Biosciences, in the press release.1 “We expect the phase 3 PRISM-1 study [NCT06608927] to be fully enrolled this year and, if positive, intend to quickly bring this new first-line treatment option to patients, with the goal of prolonging survival for those with metastatic pancreatic cancer.”

    The ARC-8 Trial

    Results from the phase 1 ARC-8 trial (NCT04104672), which evaluated quemliclustat plus chemotherapy in those with advanced pancreatic cancer, were shared in January 2024.2

    In all patients (n = 122), the median overall survival (OS) was 15.7 months (95% CI, 12.4-20.9), the 12-month OS rate was 62.7%, and the 18-month OS rate was 42.8%. In those who received quemliclustat plus gemcitabine and nab-paclitaxel (n = 29), the median OS was 19.4 months (95% CI, 12.1-23.0), the 12-month OS rate was 72.3%, and the 18-month OS rate was 54.2%. In those who received quemliclustat and zimberelimab plus gemcitabine and nab-paclitaxel (n = 61), the median OS was 14.6 months (95% CI, 10.6-21.5), the 12-month OS rate was 60.9%, and the 18-month OS rate was 43.5%. In the pooled analysis of all who received 100 mg of quemliclustat and zimberelimab plus gemcitabine and nab-paclitaxel (n = 93), the median OS was 13.9 months (95% CI, 11.1-18.7), the 12-month OS rate was 59.6%, and the 18-month OS rate was 39.3%.

    The investigators noted improvements over gemcitabine and nab-paclitaxel in benchmark trials such as the phase 3 MPACT trial (NCT00844649), which had a median OS of 8.5 months (95% CI, 7.9-9.5), the phase 3 NAPOLI-3 trial (NCT04083235), which had a median OS of 9.2 months (95% CI, 8.3-10.6), and the phase 3 CanStem111P trial (NCT02993731), which had a median OS of 11.7 months (95% CI, 10.7-12.7).

    In ARC-8, the overall median progression-free survival (PFS) was 6.3 months (95% CI, 5.4-7.7).

    In all patients, the overall response rate (ORR) was 38.5% (95% CI, 29.9%-47.8%) compared with 36.2% (95% CI, 31.4%-41.2%) in NAPOLI-3; the disease control rate (DCR) was 77.8% vs 62.3%, respectively; and stable disease was noted in 39.3% and 26.1%.

    The trial enrolled patients with first-line metastatic pancreatic ductal adenocarcinoma (PDAC). A dose-escalation phase consisted of 25 to 125 mg of quemliclustat with zimberelimab, gemcitabine, and nab-paclitaxel. The recommended dose for expansion was 100 mg of quemliclustat. In the dose-expansion phase, patients were split into 2 cohorts: cohort A (n = 26), where patients with first-line PDAC received 100 mg of quemliclustat and zimberelimab plus gemcitabine and nab-paclitaxel, and cohort B (n = 21), where patients with second-line PDAC received the same regimen. Patients in cohort A were randomly assigned, in a 2:1 ratio, to receive either 100 mg of quemliclustat plus zimberelimab, gemcitabine, and nab-paclitaxel (n = 61), or 100 mg of quemliclustat plus gemcitabine and nab-paclitaxel (n = 29).

    The median age of patients was 65.5 years; the majority were female (58%), White (93%), and had an ECOG performance status of 1 (80%). Additionally, 79% of patients had liver metastasis at baseline, 21% had prior pancreatic cancer surgery, and 15% received any prior systemic anti-cancer therapy.

    Regarding safety, any-grade treatment-related adverse events (TRAEs) occurred in 99.2% of patients; grade 3 or higher TRAEs occurred in 73.0%. Serious TRAEs and grade 5 TRAEs occurred in 27.9% and 4.1%. AEs led to dose reduction, dose delay, and study discontinuation in 53.3%, 75.4%, and 23.0%.

    The PRISM-1 Trial

    The global, randomized, double-blind phase 3 PRISM-1 trial will evaluate quemliclustat plus gemcitabine and nab-paclitaxel chemotherapy compared with placebo plus gemcitabine and nab-paclitaxel.3 The trial is intended to be fully enrolled by the end of 2025, with an expected enrollment of 610 patients who will be randomly assigned to one of the trial arms in a 2:1 ratio.

    Eligible patients will have histologically or cytologically confirmed metastatic PDAC, no previous treatment for metastatic PDAC, an ECOG performance status of 0 or 1, and at least 1 target lesion measurable by CT or MRI.3 Patients will be permitted to receive prior neoadjuvant or adjuvant therapy if completed at least 12 months before radiation, prior palliative radiotherapy if completed at least 2 weeks prior to randomization with AEs resolving to grade 1 or less, and prior placement of a biliary stent if TRAEs have improved to grade 1 or less.

    Those with a history of brain metastases or leptomeningeal metastases, prior treatment with a CD73 antagonist or inhibitor, previous treatment for locally advanced and unresectable PDAC, and underlying medical conditions will be excluded from trial participation.

    The trial’s primary end point will be OS. The secondary end points will be PFS, ORR, duration of response, DCR, and safety.

    References

    1. Arcus Biosciences’ quemliclustat receives orphan drug designation for pancreatic cancer. News release. Arcus Biosciences. July 10, 2025. Accessed July 11, 2025. https://tinyurl.com/2wa7kyu8
    2. Wainberg ZA, Mani GA, Bahary N, et al. ARC-8: Phase 1/1b randomized study of quemliclustat + gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma. J Clin Oncol. 2024;42(suppl 3):665. doi:10.1200/JCO.2024.42.3_suppl.665
    3. Study of quemliclustat and chemotherapy versus placebo and chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PRISM-1). ClinicalTrials.gov. Updated June 26, 2025. Accessed July 11, 2025. https://tinyurl.com/3tykrvpv

    Continue Reading

  • West Indies-Australia live: Third day-night Test in Jamaica

    West Indies-Australia live: Third day-night Test in Jamaica

    Live: West Indies vs Australia day-night Test in Kingston

    21st over – Justin Greaves to Khawaja

    There are just 20 minutes to lunch. Khawaja and Green have to knuckle down and get to the break, but this ball is still talking.

    FOUR! Khawaja hooks away and it’s just out of reach of a diving Mikyle Louis at square leg. Would’ve been an all-timer if he’d taken it.

    20th over – Seales to Green

    Great fielding by Shamar Joseph running and dive at wide mid-off to keep Cameron Green on strike.

    There’s a shout for LBW against Green, and Roston Chase really seems to be considering a review, but Shamar Joseph wisely talks him out of it. It was going miles down leg.

    Huge in-swing and seam beats Green’s inside edge, hitting him on the back thigh.

    19th over – Greaves again

    There’s angle and seam in to Khawaja, who’s caught on the thigh pad.

    Seamer Alzarri Joseph is walking off the field alongside one of the trainers. One to watch.

    Two more for Khawaja as Greaves pitches full and wide and it’s driven through cover.

    This outfield is looking very slow as Khawaja nails a cover drive and it looks destined for the boundary but holds up in the deep. Just two.

    18th over – Seales continues

    And Khawaja clips a single off his pads to start.

    Four! Gorgeous timing by Cameron Green just clipping a ball that was going down leg and sending it through the air over square leg.

    17th over – Green to face Greaves

    The wicket-taker continues with big Cameron Green at the crease, coming off that impressive second-innings 52 at St George’s.

    Two fantastic deliveries beat the outside edge to end the over.

    A wicket-maiden to start from Justin Greaves.

    IMMEDIATE BREAKTHROUGH! Greaves gets Konstas first ball

    Justin Greaves angles in at Sam Konstas’s pad and collects him above the knee roll.

    The umpire raises the finger and Konstas consults with Khawaja before reviewing, but DRS shows three reds and he has to go for 17.

    (AP)

    I assume he was suggesting it may have gone over or slid down leg, but Konstas was on the crease and standing right in front of all three stumps.

    Australia is down to two reviews.

    17th over – Justin Greaves gets his first go

    Sam Konstas is in his sights.

    16th over – Seales resumes

    Another one past the outside edge. It’s been a frustrating morning for all the West Indian bowlers, but Seales in particular.

    Khawaja isn’t playing at much outside off.

    He goes for the big pull shot, which is so often a release for him, but the ball isn’t quite short enough and Khawaja cops it on the thigh pad.

    15th over – Alzarri Joseph around the wicket to Usman Khawaja

    This right-armed bowling attack loves their chances of getting the left-handed Khawaja from around the wicket.

    One clip through leg is stopped by Jomel Warrican, but Khawaja gets the next in front of square leg and takes the single to move to 6 from 41.

    A gorgeous seed from Alzarri Joseph, angled in and swinging away. Drawing Konstas into the shot and beating the outside edge. Credit to Konstas for playing with a straight and still bat so as not to nick it.

    FOUR! A lovely back-foot drive through point from Konstas. Confident shot from a man who chopped on last Test.

    14th over – Jayden Seales returns to the attack

    And his first ball is down the leg side. Konstas admonishes himself for not clipping it away.

    Edged away with soft hands through the slips but Brandon King does well on the rope to flick it back to Justin Greaves and keep Konstas to just two runs.

    They’re the only runs from the over. Konstas isn’t in a rush, but looks more comfortable than he did in the first Test for sure.

    England and India dead even

    It doesn’t get much more even than the third Test between England and India at Lord’s.

    Both teams scored exactly 387 in their first innings.

    Both digs featured one century-maker who then immediately got out, supported by two 50s and a duck.

    All eyes have rightly been on Shubman Gill, Jamie Smith, Rishabh Pant etc, but KL Rahul with this first-innings ton has 336 runs for the series at 67.20.

    It’s been one for the batters, with nine players tonning up and eight players averaging over 50.

    13th over: Alzarri gets another

    Good running from the Australian pair, who get three after Konstas works one into the on-side.

    Big shout! Khawaja is struck on the pads in such a quintessentially Khawaja way. His footwork is nowhere as he’s trying to flick Alzarri through the on-side. The West Indies are up in a big way, but it’s probably sliding down. No review.

    Khawaja squeezes one out leg-side and the batters run a couple.

    Wayward and down the leg-side from Alzarri. Khawaja watches it through to Hope.

    It’s a dot to end a five run over for Australia.

    Not quite free flowing, expansive stuff from the opening pair but they’ve done extremely well to survive the first hour in Jamaica.

    We’ll have a drink.

    12th over: Shamar to continue

    Runs! Khawaja squirts one out forward of square and the batters run a single.

    Another single! Poor from Shamar, too straight and Konstas is able to work his own leg-side run this time.

    Peach! Khawaja’s footwork is nowhere as he dangles his bat at one that pitches and moves away and is collected by Shai Hope.

    First sign of aggression from Khawaja, who’s trying to pull Shamar but isn’t timing it.

    11th over: Alzarri to begin his second

    That’s a very optimistic shout from A. Joseph. Konstas is hit on the pads by one angling down leg and going over the top. No review.

    That is a peach! Konstas is cut in half by one that pitches and moves away from him.

    More assured this time from Konstas, who’s back and defending a similar ball.

    It’s seriously stodgy stuff out there – 13 runs from nearly 11 overs.

    Konstas prepares for the final ball of Alzarri’s second over.

    He’s defending and that’s yet another maiden.

    Actually, it’s not. That last ball is called a no-ball.

    The final, final ball is wide down the leg side and through to Hope.

    10th over: Shamar switches ends

    After a pretty disappointing start, Shamar Joseph is trying his luck from the other end.

    And it’s a better look on him. Coming around the wicket, Khawaja is playing and missing at a couple on a fourth stump line.

    Ouch! Khawaja cops a short one on the shoulder after shaping to come down the wicket to Shamar.

    (AP)

    Khawaja is defending to end undoubtedly Shamar’s best over of the day so far.

    9th over: A. Joseph into the attack

    Shot! First boundary of the match and it’s a good one from Sam Konstas. Alzarri’s first ball is loose and short and Konstas stands tall, swivels and pulls him in-front of square.

    The Australians will be delighted that they’ve managed to see off the first of the two Josephs.

    Not exactly thrill a minute stuff from the two batters – but they’re both still out there.

    Konstas tries his luck selling Khawaja another tight single, but the 38-year-old is having none of it.

    And Konstas is back and defending to end the over.

    8th over: Seales to Konstas again

    Edge! This one comes back into Konstas, who is back and defending unconvincingly. The ball kisses his outside edge, but it falls well short of the cordon.

    That’s better from Konstas – his first shot of authority in some time. He doesn’t get a run, but is looking good as he drives one off the back foot into the off-side infield.

    He swings at another wide one, making contact but not good contact. It dies in the square and that’s another dot.

    Too straight from Seales and Konstas is able to work one off the hip for a single to end the over.

    7th over: Seales continues to Konstas

    He’s once again looking a bit nervous out there, is Samm K.

    Seales has him defending to begin the over.

    Konstas is 1 from 18 and Khwaja 2 from 22 – not quite a swashbuckling start from the Australian openers.

    Konstas is trying to push one back past Seales but it can’t get past mid-on.

    Brutal! This one moves a mile off the seam, back in towards Konstas. He wears one on the torso.

    Konstas misses out on a wayward one down the leg-side.

    Run! Not overly convincing, but Konstas finally has his second run, courtesy of a squeezed single in front of point.

    6th over: Shamar gets another

    Well, Seales found some serious rhythm in that previous over – can Shamar do the same from the other end?

    Not to begin.

    Khawaja, once again, is more than happy to leave a couple wide ones.

    Khawaja is playing! For the first time in a couple overs, Usman is forced to use his bat. He’s defending a good one from Joseph.

    And again.

    Play in a miss! Pitching on a fourth stump line and moving away, Khawaja is defending but getting none of it.

    Much better from Joseph in the second half of that over.

    Continue Reading

  • Why the near-record high market has taken Trump’s renewed tariff blitz in stride

    Why the near-record high market has taken Trump’s renewed tariff blitz in stride

    Continue Reading

  • Better Go Mad in the Wild, Bidad, Sand City

    Better Go Mad in the Wild, Bidad, Sand City

    Miro Remo’s Better Go Mad in the Wild won the Grand Prix – Crystal Globe, the top award, at the closing ceremony of the 59th edition of the Karlovy Vary International Film Festival (KVIFF) on Saturday, where Stellan Skarsgård was also honored with the KVIFF Crystal Globe Award for his “outstanding artistic contribution to world cinema.” The Special Jury Prize went to Iranian filmmaker Soheil Beiraghi‘s fourth feature, Bidad (Outcry), whose announcement the fest had held back to ensure the safety of its creators.

    This year’s jury, consisting of Nicolas Celis, Babak Jalali, Jessica Kiang, Jiří Mádl, and Tuva Novotny, lauded the “delightfully inventive documentary” Better Go Mad as “a funny valentine to the fading art of being true to yourself” and “a portrait of bickering twin brothers who may live a weird, off-grid life on their dilapidated farm, but who, in a world as mad as ours, actually might be the sanest people on Earth.”

    Concluded the jury: “In the lifestyle it portrays, but also in the filmmaking risks it takes and the raucously loving brotherhood it admires, Better Go Mad in the Wild feels like a gulp of fresh, woody air, or a quick dip in an outdoor pond, or a moment of contemplation as a cow chews on your beard. In short, it feels like being free.”

    Meanwhile, the jury called Bidad, about a Gen Z girl who sings in the streets despite rules that forbid that in Iran, “as courageous in its constantly unexpected narrative turns, as it careens through different genre terrains as energetically as it rolls through the different suburbs of Tehran. It concluded: “Morphing from social-injustice thriller into family melodrama into a triumph-over-adversity arc, it is most striking as a gonzo lovers-on-the-run romance, shot through with punk energy and spiky personality that ends on an ambivalent yet optimistic note — because where there’s this much life, there’s hope.”

    ‘Bidad’

    Courtesy of KVIFF

    This year’s best director award went to two films: Lithuanian cinematographer Vytautas Katkus’ feature directorial debut The Visitor, a meditation on solitutde, as well as Nathan Ambrosioni’s Out of Love, a reflection on family and co-existence.

    Lauding the “deeply impressive directorial statements,” the jury said that Katkus “truly exploits the creative freedom that a director perhaps only ever properly enjoys with their first film, displaying an uncompromised, idiosyncratic vision that is both dazzlingly precise in its detail and dreamily peculiar as whole.” It also noted that Ambrosioni “demonstrates a maturity, compassion and polish far beyond his years in the moving and beautifully crafted Out of Love in which a rich yet understated presentation that allows the terrific all-ages acting ensemble to deliver intensely felt, empathetic performances.”

    In the acting categories, Pia Tjelta was honored with the best actress award for her role in the political relationship drama Don’t Call Me Mama, Àlex Brendemühl won the best actor honor for his role in the rape drama When a River Becomes the Sea, and Kateřina Falbrová received a special jury mention for her role in the sexual abuse drama Broken Voices.

    And the Právo Audience Award winner ended up being the fest opening film, We’ve Got to Frame It! (A Conversation With Jiří Bartoška in July 2021), featuring insights and laughs courtesy of the long-term fest president who died recently.

    The fourth edition of Karlovy Vary’s Proxima competition, which focuses on bold works by young filmmakers and renowned auteurs alike, revealed Bangladeshi director Mahde Hasan’s Sand City, a movie about harsh life in a metropolis, as its winner, decided by the jury of Yulia Evina Bhara, Noaz Deshe, Nelson Carlos De Los Santos Arias, and Marissa Frobes. “A realm unknown, where architecture breathes and silence screams,” it wrote. “Time drips sideways in this fractured hourglass, and color spills like memory. In Sand City, cinema becomes a trembling map of the strange, abandoned, and intimate at the edge of sense.”

    ‘Sand City’

    Courtesy of KVIFF

    Meanwhile, the Proxima Special Jury Prize was bestowed upon Federico Atehortúa Arteaga’s Forensics, an experimental essay on missing persons. “This award goes to a film that carries forward the tradition of swimming against the current of globalized violence — with truth, with ethics, and above all, with poetry,” the jury said.

    And Manoël Dupont’s Before/After, which explores baldness and queer identity, received a special mention in the Proxima lineup.

    The non-statutory awards at KVIFF, namely the Europa Cinemas Label honor for the best European film at KVIFF 2025, the Fipresci Award, as well as the Grand Prize of the Ecumenical Jury, put a spotlight on three different movies.

    Rebuilding, directed by Max Walker-Silverman and starring Josh O’Connor, won the Ecumenical Jury’s Grand Prize, while the jury gave a commendation to Cinema Jazireh, directed by Gözde Kural. The Europa Cinemas Label honor went to Broken Voices, and the Fipresci honor was awarded to Before/After.

    The 2025 edition of the Karlovy Vary fest, which has a reputation as Central Europe’s largest cinema party, had opened with the presentation of KVIFF President’s Awards to Peter Sarsgaard and Vicky Krieps, a film about late long-time KVIFF president Jiří Bartoška, and a concert by U.K. act La Roux.

    Continue Reading